The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

22 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Sulfonamides as Selective NaEBI
Amgen
Sulfonamides as Selective NaEBI
Amgen
Development of New Benzenesulfonamides As Potent and Selective NaEBI
Bristol-Myers Squibb
Sulfonamides as Selective NaEBI
Amgen
Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models.EBI
Xenon Pharmaceuticals
Discovery of (phenoxy-2-hydroxypropyl)piperidines as a novel class of voltage-gated sodium channel 1.7 inhibitors.EBI
Daiichi Sankyo
Engineering potent and selective analogues of GpTx-1, a tarantula venom peptide antagonist of the Na(V)1.7 sodium channel.EBI
Amgen
Discovery of Selective Inhibitors of NaEBI
Siteone Therapeutics
Discovery of pyridyl urea sulfonamide inhibitors of NaEBI
Moma Therapeutics
Discovery of Arylsulfonamide NaEBI
Merck
Discovery of Potent, Selective, and State-Dependent NaEBI
Lupin
Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors.EBI
Amgen
Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective NaEBI
Bristol-Myers Squibb Research And Development
Challenges and Opportunities for Therapeutics Targeting the Voltage-Gated Sodium Channel Isoform NaEBI
Siteone Therapeutics
Design of Conformationally Constrained Acyl Sulfonamide Isosteres: Identification of N-([1,2,4]Triazolo[4,3- a]pyridin-3-yl)methane-sulfonamides as Potent and Selective hNaEBI
Xenon Pharmaceuticals
Highly potent and selective NaEBI
Pfizer
Discovery of Tarantula Venom-Derived NaEBI
Amgen
Discovery of a biarylamide series of potent, state-dependent NaEBI
Amgen
The discovery of benzoxazine sulfonamide inhibitors of NaEBI
Amgen
Discovery of non-zwitterionic aryl sulfonamides as NaEBI
Bristol-Myers Squibb Research And Development
Benzoxazolinone aryl sulfonamides as potent, selective NaEBI
Merck
Discovery of selective, orally bioavailable, N-linked arylsulfonamide NaEBI
Department Of Discovery Chemistry Merck